摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-Phenyl-7-acetyl-8-hydroxychinolin | 93325-09-8

中文名称
——
中文别名
——
英文名称
5-Phenyl-7-acetyl-8-hydroxychinolin
英文别名
1-(8-Hydroxy-5-phenylquinolin-7-yl)ethanone
5-Phenyl-7-acetyl-8-hydroxychinolin化学式
CAS
93325-09-8
化学式
C17H13NO2
mdl
——
分子量
263.296
InChiKey
JZVCTHJWXFRYKG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    50.2
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • Heterocyclic compounds having inhibitory activity against hiv integrase
    申请人:Murai Hitoshi
    公开号:US20060128669A1
    公开(公告)日:2006-06-15
    A heterocyclic compound of the formula (I): wherein B 1 is —C(R 2 )═ or —N═; R 1 ′ is H, etc.; one of R 1 and R 2 is -Z 1 -Z 2 -Z 3 -R 5 wherein Z 1 and Z 3 are independently single bond, optionally substituted alkylene, etc.; Z 2 is single bond, optionally substituted alkylene, etc.; R 5 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R 1 and R 2 is H; -A 1 - is —C(—Y)═C(—R A )—C(—R 3 )═C(—R 4 )—, etc. wherein Y is OH, etc.; R A is —COR 7 wherein R 7 is OH, etc.; one of R 3 and R 4 is carboxy, etc., and the other of R 1 and R 2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.
    化合物的公式(I)为杂环化合物,其中B1为—C(R2)═或—N═; R1'为H等; R1和R2中的一个是—Z1-Z2-Z3-R5,其中Z1和Z3分别为单键,可选地取代的烷基等; Z2为单键,可选地取代的烷基等; R5为可选地取代的芳基,可选地取代的杂环芳基等,而R1和R2中的另一个是H; -A1-为—C(—Y)═C(—RA)—C(—R3)═C(—R4)—等,其中Y为OH等; RA为—COR7,其中R7为OH等; R3和R4中的一个是羧基等,而R1和R2中的另一个是H等,其为前药、药学上可接受的盐以及其溶剂化物,具有抗病毒活性,特别是对HIV整合酶的抑制活性,以及含有该化合物的制药组合物,特别是抗HIV药物。
  • Heterocyclic compounds having inhibitory activity against HIV integrase
    申请人:Murai Hitoshi
    公开号:US20060247212A1
    公开(公告)日:2006-11-02
    A heterocyclic compound of the formula (I): wherein B 1 is —C(R 2 )═ or —N═; R 1 ′ is H, etc.; one of R 1 and R 2 is -Z 1 -Z 2 -Z 3 -R 5 wherein Z 1 and Z 3 are independently single bond, optionally substituted alkylene, etc.; Z 2 is single bond, optionally substituted alkylene, etc.; R 1 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R 1 and R 2 is H; -A 1 - is —C(—Y)═C(—R A )—C(—R 3 )═C(—R 4 )—, etc. wherein Y is OH, etc.; R A is —COR 7 wherein R 7 is OH, etc.; one of R 3 and R 4 is carboxy, etc., and the other of R 1 and R 2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.
    化合物的式子为(I)的杂环化合物:其中B1为—C(R2)═或—N═;R1'为H等;R1和R2中的一个为-Z1-Z2-Z3-R5,其中Z1和Z3分别为单键,可选地取代的烷基等;Z2为单键,可选地取代的烷基等;R1为可选地取代的芳基,可选地取代的杂环芳基等,而R1和R2中的另一个为H;-A1-为—C(—Y)═C(—RA)—C(—R3)═C(—R4)—等,其中Y为OH等;RA为—COR7,其中R7为OH等;R3和R4中的一个为羧基等,而R1和R2中的另一个为H等。该化合物的前药、药学上可接受的盐和其溶剂化物具有抗病毒活性,特别是对HIV整合酶的抑制活性,以及含有该化合物的药物组合物,尤其是抗HIV药物。
  • HETEROCYCLIC COMPOUND HAVING HIV INTEGRASE INHIBITORY ACTIVITY
    申请人:SHIONOGI & CO., LTD.
    公开号:EP1541558A1
    公开(公告)日:2005-06-15
    A heterocyclic compound of the formula (I): wherein B1 is -C(R2)= or -N=; R1' is H, etc.; one of R1 and R2 is -Z1-Z2-Z3-R5 wherein Z1 and Z3 are independently single bond, optionally substituted alkylene, etc.; Z2 is single bond, optionally substituted alkylene, etc.; R5 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R1 and R2 is H; -A1- is -C(-Y)=C(-RA)-C(-R3)=C(-R4)-, etc. wherein Y is OH, etc.; RA is -COR7 wherein R7 is OH, etc.; one of R3 and R4 is carboxy, etc., and the other of R1 and R2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.
    式 (I) 的杂环化合物: 其中 B1 是 -C(R2)= 或 -N=;R1' 是 H 等;R1 和 R2 中的一个是 -Z1-Z2-Z3-R5,其中 Z1 和 Z3 独立地是单键、任选取代的亚烷基等;Z2 是单键、任选取代的亚烷基等;R5 是任选取代的芳基、任选取代的杂芳基等、R1和R2中的另一个是H;-A1-是-C(-Y)=C(-RA)-C(-R3)=C(-R4)-等,其中Y是OH等;RA是-COR7,其中R7是OH等;R3和R4中的一个是羧基等、R1和R2中的另一个是H等,其原药、其药学上可接受的盐和其溶液,具有抗病毒活性,特别是对HIV整合酶的抑制活性,以及含有其的药物组合物,特别是抗HIV药物。
  • Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity
    申请人:——
    公开号:US20040127708A1
    公开(公告)日:2004-07-01
    A compound of the formula (I): 1 wherein Z 4 , Z 5 and Z 9 each is independently carbon atom or nitrogen atom; Y is hydroxy, mercapto or amino; R A is a group of the formula: 2 (wherein C ring is nitrogen-containing heteroaryl) has an inhibitory activity against integrase.
    式 (I) 的化合物: 1 其中 Z 4 , Z 5 和 Z 9 各自独立地为碳原子或氮原子; Y 为羟基、巯基或基; R A 是式中的一个基团: 2 (其中 C 环为含氮杂芳基)对整合酶具有抑制活性。
  • NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY
    申请人:SHIONOGI & CO., LTD.
    公开号:EP1375486B1
    公开(公告)日:2008-10-15
查看更多